trending Market Intelligence /marketintelligence/en/news-insights/trending/NMTmojwVx4bwgX4V-lmE0Q2 content esgSubNav
In This List

Pharmena Q3 profit climbs YOY


Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

451 Research Podcast

Next in Tech | Episode 42: AI/ML Infrastructure


Automating Credit Risk Surveillance Using Statistical Models

Case Study

Searching for Alpha with Textual Data

Pharmena Q3 profit climbs YOY

Pharmena SA said its normalized net income for the third quarter amounted to 111,880 zlotys, a gain from 2,500 zlotys in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin climbed to 2.5% from 0.1% in the year-earlier period.

Total revenue decreased 5.1% year over year to 4.5 million zlotys from 4.7 million zlotys, and total operating expenses declined 10.0% on an annual basis to 4.2 million zlotys from 4.7 million zlotys.

Reported net income came to 33,000 zlotys, or 0 groszy per share, compared to a loss of 88,000 zlotys, or a loss of 1 groszy per share, in the prior-year period.

As of Nov. 14, US$1 was equivalent to 4.12 zlotys.